Investment Rating - The report maintains a "Buy" rating for Haidilao (06862.HK) [1] Core Views - The company is focusing on steady progress and active advancement, with expectations for revenue and profit growth driven by operational optimizations and new brand incubations [8] - The "Red Pomegranate" plan has shown positive results, with 11 new restaurant brands and 74 new stores established by the end of 2024, indicating a potential second growth curve for the company [8] - The company is implementing a strict selection mechanism for franchisees to ensure quality and service standards, with 13 franchise stores already operational by the end of 2024 [8] - Digital upgrades and supply chain optimizations are being pursued through AI technology and data analysis, enhancing customer satisfaction and operational efficiency [8] Financial Projections - Total revenue is projected to grow from 41,622 million RMB in 2023 to 47,244 million RMB by 2027, with a compound annual growth rate (CAGR) of approximately 3.62% [1] - Net profit attributable to shareholders is expected to increase from 4,499 million RMB in 2023 to 5,269 million RMB in 2027, reflecting a CAGR of about 4.77% [1] - The earnings per share (EPS) is forecasted to rise from 0.81 RMB in 2023 to 0.95 RMB in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 17.21 to 14.70 over the same period [1]

Investment Rating - The report maintains a "Buy" rating for Xiaomi Group-W (01810.HK) [1] Core Views - The company continues to focus on the "people, vehicles, and home" ecosystem, launching new products such as the YU7 SUV and the Xuanjie chips, which are expected to drive growth [7] - The YU7 SUV is positioned as a high-performance luxury vehicle with impressive specifications, including a maximum horsepower of 690 PS and a range of 835 km, which is the highest for mid-to-large electric SUVs [7] - The self-developed Xuanjie O1 chip marks Xiaomi as the fourth company globally to design a 3nm process mobile SoC, enhancing its product capabilities [7] - The company has seen a 15.7% year-on-year increase in total smartphone shipments, with a growing market share in both global and domestic markets [7] - The report forecasts significant revenue growth, with total revenue expected to reach 691.16 billion yuan by 2027, and net profit projected to reach 59.31 billion yuan in the same year [1][8] Financial Projections - Total revenue projections for Xiaomi Group-W are as follows: - 2023: 270.97 billion yuan - 2024: 365.91 billion yuan - 2025: 483.50 billion yuan - 2026: 608.29 billion yuan - 2027: 691.16 billion yuan - Net profit projections are as follows: - 2023: 17.48 billion yuan - 2024: 23.66 billion yuan - 2025: 34.31 billion yuan - 2026: 46.73 billion yuan - 2027: 59.31 billion yuan [1][8] - The report indicates a steady increase in earnings per share (EPS), projected to reach 2.29 yuan by 2027 [1][8] Market Position - Xiaomi's market share in the high-end smartphone segment has increased, with a 3% year-on-year rise to 23.3% in 2024 [7] - The company plans to expand its retail presence internationally, aiming to open approximately 10,000 new Xiaomi stores overseas in the next five years [7]

Investment Rating - The report maintains an "Accumulate" rating for the electric equipment industry [1] Core Views - The humanoid robot production is set to ramp up, with significant market potential projected at over 100 million units, corresponding to a market space exceeding 15 trillion yuan. The year 2025 is anticipated to be a pivotal year for mass production [7][8] - The electric vehicle sector shows strong growth, with April sales of new energy vehicles reaching 1.23 million units, a year-on-year increase of 44%. The overall market is expected to grow by 25% in 2025, driven by consumption stimulus policies [27][29] - The energy storage market is experiencing a surge, particularly in the U.S. and Germany, with significant increases in installed capacity expected in 2025. The U.S. is projected to add 19-20 GW of new installations this year, doubling the previous year's figures [9][14] Industry Trends Humanoid Robots - The humanoid robot market is in its early stages, with a projected long-term market space of over 100 million units. The current phase is likened to the early days of the electric vehicle market, indicating substantial growth potential [7][8] - Key catalysts for growth include updates from major players like Tesla and advancements from domestic tech companies in humanoid robotics [7] Energy Storage - The U.S. energy storage market saw a 984 MW increase in March, with a year-on-year growth of 85%. The average storage duration is approximately 3.4 hours, indicating a robust demand for energy storage solutions [9][14] - Germany's energy storage market is also expanding, with expectations of doubling capacity by 2025 due to regulatory pressures for renewable energy integration [14] Electric Vehicles - April saw a total of 1.23 million new energy vehicles sold in China, with significant contributions from leading manufacturers like BYD and Xpeng. The market is expected to continue its upward trajectory, supported by favorable policies [27][29] Company Summaries - CATL (宁德时代) is highlighted as a global leader in power and energy storage batteries, with a low valuation and strong growth prospects [6] - BYD is noted for its continuous improvement in electric vehicle sales and structural upgrades, maintaining a strong market position [6] - Other companies such as Sunshine Power (阳光电源) and Keda Li (科达利) are also recommended for their robust growth and market leadership in their respective segments [6]

Investment Rating - The report maintains a "Buy" rating for Xiaomi Group-W (01810.HK) [1] Core Views - The company continues to focus on the "people, vehicles, and home" ecosystem, launching new products such as the YU7 SUV and the Xuanjie chips, which are expected to drive growth [7] - The YU7 SUV is positioned as a high-performance luxury vehicle with impressive specifications, including a maximum horsepower of 690 PS and a range of 835 km, which is the highest for mid-to-large electric SUVs [7] - The self-developed Xuanjie O1 chip marks Xiaomi as the fourth company globally to design a 3nm process mobile SoC, enhancing its product capabilities [7] - The company is expanding its high-end product offerings, with a 15.7% year-on-year increase in total smartphone shipments in 2024, and a 3% increase in the domestic high-end smartphone market share [7] Financial Projections - Total revenue is projected to grow from CNY 270.97 billion in 2023 to CNY 691.16 billion by 2027, with a compound annual growth rate (CAGR) of 13.62% [1] - Net profit attributable to shareholders is expected to increase significantly from CNY 17.48 billion in 2023 to CNY 59.31 billion in 2027, reflecting a CAGR of 26.93% [1] - The earnings per share (EPS) is forecasted to rise from CNY 0.67 in 2023 to CNY 2.29 in 2027 [1] - The price-to-earnings (P/E) ratio is projected to decrease from 73.19 in 2023 to 21.56 in 2027, indicating improving valuation [1] Market Position - Xiaomi's market capitalization is approximately CNY 1,043.39 million, with a closing price of HKD 53.00 [5] - The company has a price-to-book (P/B) ratio of 6.47 and a debt-to-asset ratio of 53.07% [6] - The company aims to expand its retail presence internationally, planning to open around 10,000 new Xiaomi stores overseas in the next five years [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is focusing on steady progress and active advancement, with a strong emphasis on optimizing its operational model and expanding its store network [8] - The "Red Pomegranate" plan has shown positive results, with the company successfully incubating new brands and expanding its market presence [8] - The company is leveraging digital upgrades and supply chain optimization to enhance customer satisfaction and operational efficiency [8] Financial Projections - Total revenue is projected to grow from 41,622 million in 2023 to 47,244 million by 2027, with a compound annual growth rate (CAGR) of approximately 3.62% [1] - Net profit attributable to shareholders is expected to increase from 4,499 million in 2023 to 5,269 million by 2027, reflecting a CAGR of about 4.77% [1] - The earnings per share (EPS) is forecasted to rise from 0.81 in 2023 to 0.95 by 2027, indicating a steady growth trajectory [1] Operational Strategy - The company is implementing a bottom-up site selection mechanism and strict standards for franchisee entry, focusing on product, scene, and management optimization [8] - The company has initiated a franchise model with a rigorous selection process, ensuring quality and standardization across its outlets [8] - The company has launched multiple new restaurant brands under the "Red Pomegranate" initiative, aiming to create a second growth curve [8] Digital and Supply Chain Enhancements - The company is utilizing big data and AI technologies to improve customer feedback processing and enhance service quality [8] - The proprietary "HiHi System" app has achieved over 20,000 monthly clicks, indicating strong user engagement [8] - The deployment of over 50 AI robots across various operational areas is aimed at improving efficiency and customer service [8]

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 国产创新药闪耀 ASCO 国际舞台 2025 年 05 月 25 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -18% -15% -12% -9% -6% -3% 0% 3% 6% 9% 12% 15% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 医药生物 沪深300 相关研究 《三抗药物研发进入快车道，建议关 注泽璟制药、三生制药等》 2025-05-18 | 1. 本周及年初至今各医药股收益情况 4 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2. 中国创新药闪耀 ASCO 会议，口头报告数量再创新高 7 | | | | | | | | | 2.1. 2025 ASCO 摘要披露，众多国产抗体和 ADC 类分子亮相口头报告 7 | | | | | | | | | 后线治疗不断迎 ...

证券研究报告·行业跟踪周报·建筑材料 建筑材料行业跟踪周报 继续推荐消费建材 2025 年 05 月 25 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 黄诗涛 执业证书：S0600521120004 huangshitao@dwzq.com.cn 证券分析师 房大磊 执业证书：S0600522100001 fangdl@dwzq.com.cn 证券分析师 石峰源 执业证书：S0600521120001 shify@dwzq.com.cn 行业走势 -26% -22% -18% -14% -10% -6% -2% 2% 6% 10% 14% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 建筑材料 沪深300 相关研究 《期待服务消费加速》 2025-05-18 《 2024 年年报及 2025 年一季报综 述：需求继续承压，行业竞争出现缓 和信号》 2025-05-14 东吴证券研究所 1 / 21 请务必阅读正文之后的免责声明部分 ◼ 本周（2025.5.19–2025.5.23，下同）：本周建筑材料板块（SW）涨跌幅- 1 ...

证券研究报告·行业跟踪周报·建筑装饰 建筑装饰行业跟踪周报 基建投资保持平稳，关注水利、洁净室等 专业工程领域 增持（维持） [Table_Tag] [投资要点 Table_Summary] （2）出海方向：2025 年前 4 个月我国对外承包工程完成营业额 471.1 亿美元，同比增长 6.8%；新签合同额 765.9亿美元，同比增长 22.4%； 其中在共建"一带一路"国家新签合同额 645.4 亿美元，同比增长 17.4%；美国关税摩擦和全球贸易摩擦升级，后续外交博弈、贸易摩擦 或加剧，一带一路战略推进或加码，预期未来中欧合作、东盟地区合 作有望更加密切，基建合作仍是重要形式，海外工程需求景气度有望 保持，海外工程业务有望受益，后续预计逐渐兑现到订单和业绩层 面。建议关注国际工程板块，个股推荐中材国际、上海港湾，建议关 注中工国际、北方国际、中钢国际等。 执业证书：S0600521120001 shify@dwzq.com.cn 行业走势 （3）需求结构有亮点，新业务增量开拓下的投资机会：部分专业制造 工程细分领域、节能降碳以及新能源相关的基建细分领域景气度较 高，有相关转型布局的企业有望受益，建议关注 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The A-share pharmaceutical index has increased by 1.8% this week and 4.3% year-to-date, outperforming the CSI 300 by 1.9% and 5.6% respectively [3][8] - The H-share biotechnology index has seen a rise of 6.7% this week and 36.4% year-to-date, outperforming the Hang Seng Technology Index by -7.4% and 19% [3][8] - The report highlights a significant increase in the number of domestic innovative drugs presented at the ASCO conference, with 25 oral presentations and 24 rapid oral presentations, marking a new high [14] Summary by Sections Industry Performance - A-share raw materials (+4.0%), chemical drugs (+3.6%), biological products (+1.7%), medical services (+1.4%), and pharmaceutical commerce (+1.2%) have shown notable price increases, while medical devices (+0.5%) and traditional Chinese medicine (+0.2%) have seen smaller gains [3][8] - Top performers in A-shares this week include Shengguojian (+100%), Haichen Pharmaceutical (+52%), and Shutaishen (+49%), while the largest declines were seen in Xin Ganjiang (-12%), Gongdong Medical (-10%), and Jinhao Medical (-9%) [3][8] R&D Developments - The report notes significant advancements in the development of innovative drugs, particularly in antibody and ADC molecules, with several companies like China Biopharmaceuticals and Innovent Biologics showcasing promising clinical data [14] - GlaxoSmithKline's IL-5 monoclonal antibody has been approved for treating COPD, marking a milestone as the first IL-5 drug approved for this indication [3] Investment Recommendations - The report suggests a ranking of favored sub-industries: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [9] - Recommended stocks based on growth potential include BeiGene, Hengrui Medicine, and Innovent Biologics, while undervalued stocks in traditional Chinese medicine include Zhaoli Pharmaceutical and Dong'e Ejiao [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a net operating revenue of 13.8 billion yuan in Q1 2025, representing a year-on-year growth of 16%, in line with Bloomberg consensus expectations. The adjusted EBITDA was 4.2 billion yuan, with an EBITDA margin of 30%. The Non-GAAP net profit was 4.2 billion yuan, showing a year-on-year increase of 3%, which is better than Bloomberg consensus expectations [7] - The international business continues to grow significantly, with outbound travel maintaining stable growth. The cross-border flight capacity has recovered to 83% of pre-pandemic levels, and hotel and flight bookings for outbound travel have exceeded 120% of the same period in 2019, outperforming the market by 30%-40% [7] - Domestic tourism demand remains strong, with inbound tourism also experiencing robust growth. In Q1, the number of inbound travelers increased by 40% year-on-year, with 75% coming from visa-free regions. The company's platform saw a nearly 100% year-on-year increase in inbound bookings, with hotel bookings in major visa-free countries in the Asia-Pacific region surging over 240% [7] - The company continues to focus on enhancing its international business through better product experiences and customer service, with a sales expense ratio of approximately 21% in Q1, which is better than expected [7] - The profit forecast for 2025-2027 has been adjusted, with the adjusted net profit for 2025, 2026, and 2027 projected at 17.6 billion, 19.7 billion, and 22 billion yuan respectively, corresponding to P/E ratios of 18, 16, and 15 times [7] Financial Summary - Total revenue for 2023 is projected at 44.51 billion yuan, with a year-on-year growth of 122.12%. For 2024, revenue is expected to reach 53.29 billion yuan, reflecting a growth of 19.73% [1] - The company's net profit attributable to shareholders for 2023 is estimated at 9.92 billion yuan, with a staggering year-on-year growth of 606.91%. The forecast for 2024 is 17.07 billion yuan, indicating a growth of 72.08% [1] - The latest diluted EPS for 2023 is projected at 13.90 yuan per share, with a P/E ratio of 32.27 times [1]